Macular Telangiectasia Type
📧 Sign up to get email alerts when something new happens for Macular Telangiectasia Type.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-03Clinical Trial Update: Phase 4 Study: Long-term Safety and Efficacy of NT-501 in MacTel Type 2, Including Sham Procedure Participants [Phase 4]
Phase 4 clinical trial update for NT-501 assessing long-term safety and efficacy in Macular Telangiectasia Type 2, including sham procedure …
-
CLINICAL_TRIALS trial_result · 2026-01-26Clinical Trial Update: Comparative Multicenter Randomized Study of Aflibercept Versus Placebo in Macular Telangiectasia Type 1 [Phase 3]
Phase 3 multicenter randomized trial comparing aflibercept to placebo for macular telangiectasia type 1 has been terminated. The document no…
-
CLINICAL_TRIALS trial_result · 2026-01-15Clinical Trial Update: Study of Serine Supplementation to Protect Vision in MacTel [Phase 3]
Phase 3 study evaluating serine supplementation (L-Serine) to protect vision in Macular Telangiectasia Type 2 (MacTel); the trial is not yet…
-
CLINICAL_TRIALS trial_result · 2025-07-10Clinical Trial Update: A Study to Determine the Safety and Efficacy of NT-501 With MHFM [Phase 3]
A Phase 3 clinical trial evaluating NT-501 with MHFM for Macular Telangiectasia Type 2 is currently active but not recruiting.
-
CLINICAL_TRIALS trial_result · 2025-05-09Clinical Trial Update: Extension Study of NT-501 Ciliary Neurotrophic Factor (CNTF) Implant for Macular Telangiectasia (MacTel) [Phase 2]
An extension study of Neurotech's NT-501 CNTF implant for Macular Telangiectasia Type 2 has completed the Phase 2 trial, with results posted…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-03-26Clinical Trial Update: Safety Study to Evaluate Bilateral CNTF Implants in Subjects With MacTel Type 2 [Phase 2]
Phase 2 safety study evaluating bilateral CNTF implants in Macular Telangiectasia Type 2 has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2024-09-24Clinical Trial Update: A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol A [Phase 3]
Phase 3 study evaluating NT-501 for Macular Telangiectasia Type 2 has completed enrollment with results posted in 2024, reporting data on sa…
-
CLINICAL_TRIALS trial_result · 2024-09-24Clinical Trial Update: A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol B [Phase 3]
Phase 3 study evaluating NT-501 for macular telangiectasia type 2 completed protocol B with results posted.
-
CLINICAL_TRIALS trial_result · 2024-03-13Clinical Trial Update: Serine and Fenofibrate Study in Patients With MacTel Type 2 [Phase 2]
A Phase 2 clinical trial investigating serine and fenofibrate for Macular Telangiectasia Type 2 is ongoing, with status currently unknown.
-
CLINICAL_TRIALS trial_result · 2018-09-12Clinical Trial Update: A Phase 2 Multicenter Randomized Clinical Trial of CNTF for MacTel [Phase 2]
Phase 2 multicenter randomized trial evaluating CNTF for Macular Telangiectasia Type 2 has completed.
-
CLINICAL_TRIALS trial_result · 2017-07-02Clinical Trial Update: Injected Ranibizumab to Treat Macular Telangiectasia Without New Blood Vessel Formation [Phase 1]
Phase 1 trial evaluating intravitreal ranibizumab for macular telangiectasia without neovascularization has completed.
-
CLINICAL_TRIALS trial_result · 2017-06-23Clinical Trial Update: The Role of Macular Pigment Carotenoids in the Pathogenesis and Treatment of Macular Telangiectasia Type 2 (MacTel)
This clinical trial update examines the role of macular pigment carotenoids in the pathogenesis and potential treatment of Macular Telangiec…
-
CLINICAL_TRIALS trial_result · 2016-11-22Clinical Trial Update: Ciliary Neurotrophic Factor (CNTF) Safety Trial in Patients With Macular Telangiectasia (Mactel) [Phase 1]
Phase 1 safety trial of Ciliary Neurotrophic Factor (CNTF) in patients with macular telangiectasia completed.
-
CLINICAL_TRIALS trial_result · 2009-09-22Clinical Trial Update: Ranibizumab to Treat Type 2 Idiopathic Macular Telangiectasia (RAMA-Trial) [Phase 2]
A Phase 2 RAMA-Trial evaluating ranibizumab for macular telangiectasia type 2 has completed.
-
CLINICAL_TRIALS trial_result · 2007-12-06Clinical Trial Update: MPOD in Macular Teleangiectasia Following Supplementation of Lutein and Zeaxanthin
This clinical trial update assesses changes in macular pigment density (MPOD) after supplementation with lutein and zeaxanthin in macular te…